

6 References

1. Bianchi G, Anderson KC. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back. *CA Cancer J Clin.* 2014;64(6):422-444.
2. Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. *Nat Rev Dis Primers.* 2017;3:17046.
3. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. *Leukemia.* 2009;23(1):3-9.
4. Palumbo A, Anderson K. Multiple myeloma. *N Engl J Med.* 2011;364(11):1046-1060.
5. van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. *Lancet.* 2021;397(10272):410-427.
6. Terpos E, Mikhael J, Hajek R, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. *Blood Cancer J.* 2021;11(2):40.
7. Schluterman KO, Fassas AB, Van Hemert RL, Harik SI. Multiple myeloma invasion of the central nervous system. *Arch Neurol.* 2004;61(9):1423-1429.
8. Ramsenthaler C, Osborne TR, Gao W, et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. *BMC Cancer.* 2016;16:427.
9. Ramsenthaler C, Kane P, Gao W, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. *Eur J Haematol.* 2016;97(5):416-429.
10. Kamal M, Wang XS, Shi Q, et al. Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma. *Support Care Cancer.* 2021;29(1):467-475.
11. Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. *JAMA.* 2022;327(5):464-477.
12. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER). Cancer stat facts: myeloma. <https://seer.cancer.gov/statfacts/html/mulmy.html>. Accessed March 27, 2024.
13. Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. *Lancet Haematol.* 2022;9(2):e143-e161.
14. Mohan M, Nagavally S, Dhakal B, et al. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. *Blood Adv.* 2022;6(8):2466-2470.

15. Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M. Health related quality of life in a nationally representative sample of haematological patients. *Eur J Haematol*. 2009;83(2):139-148.
16. Robinson D, Jr., Esseltine DL, Regnault A, Meunier J, Liu K, van de Velde H. The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials. *Br J Haematol*. 2016;174(3):368-381.
17. Baz R, Lin HM, Hui AM, et al. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. *Support Care Cancer*. 2015;23(9):2789-2797.
18. Larsen RF, Jarden M, Minet LR, Frølund UC, Möller S, Abildgaard N. Physical function in patients newly diagnosed with multiple myeloma; a Danish cohort study. *BMC Cancer*. 2020;20(1):169.
19. Blade J, Beksac M, Caers J, et al. Extramedullary disease in multiple myeloma: a systematic literature review. *Blood Cancer J*. 2022;12(3):45.
20. Moreau P MM, Goldschmidt H, et al. . Outcomes of patients with extramedullary disease in triple-class exposed relapsed/refractory multiple myeloma from the LocoMMotion + MoMMent Studies. *Blood*. 2023;142:4698.
21. Epstein J, Walker R. Myeloma and bone disease: "the dangerous tango". *Clin Adv Hematol Oncol*. 2006;4(4):300-306.
22. Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. *Am Fam Physician*. 2017;95(6):373-383A.
23. Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. *J Clin Oncol*. 2016;34(13):1544-1557.
24. Diaz-delCastillo M, Chantry AD, Lawson MA, Heegaard AM. Multiple myeloma—a painful disease of the bone marrow. *Semin Cell Dev Biol*. 2021;112:49-58.
25. Jurczynszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. *Am J Hematol*. 2016;91(6):575-580.
26. Egan PA, Elder PT, Deighan WI, O'Connor SJM, Alexander HD. Multiple myeloma with central nervous system relapse. *Haematologica*. 2020;105(7):1780-1790.
27. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. *J Clin Oncol*. 2005;23(36):9219-9226.

TALVEY™ (talquetamab-tgvs) US Prix Galien submission. [June 30th, 2025]

28. de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. *Biomed Res Int*. 2014;2014:232546.
29. Rasche L, Schinke C, Maura F, et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. *Nat Commun*. 2022;13:4517.
30. Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. *Leukemia*. 2017;31(11):2443-2448.
31. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. *N Engl J Med*. 2015;373(13):1207-1219.
32. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. *Lancet*. 2016;387(10027):1551-1560.
33. Dhanasiri S, Hollier-Hann G, Stothard C, Dhanda DS, Davies FE, Rodriguez-Otero P. Treatment patterns and outcomes in triple-class exposed patients with relapsed and refractory multiple myeloma: Findings from the multinational ITEMISE study. *Clin Ther*. 2021;43(11):1983-1996.e3.
34. Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. *Int J Mol Sci*. 2021;22(9):4462.
35. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. *N Engl J Med*. 2019;381(8):727-738.
36. Malin Hultcrantz DK, Ravi Vij, Fernando Escalante, Nirali Kotowsky, Jacopo Bitetti, Christine Mackay, Natalie Boytsov, Leena Camadoo-O'Byrne, Guillaume Germain, Mei Sheng Duh, François Laliberté, Malena Mahendran, Ana Urosevic, Hans C. Lee. Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study. *Blood*. 2022;140:10124–10126.
37. Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. *Nat Med*. 2023;29:2259-2267.
38. Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. *N Engl J Med*. 2022;387(6):495-505.
39. Munshi NC, Anderson LD, Jr., Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. *N Engl J Med*. 2021;384(8):705-716.
40. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. *Am J Hematol*. 2020;95(5):548-567.
41. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. *N Engl J Med*. 2023;389(4):335-347.

42. Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. *Lancet*. 2021;398(10301):665-674.
43. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. *BMC Cancer*. 2020;20:1087.
44. Paul B, Rodriguez C, Usmani SZ. BCMA-targeted biologic therapies: the next standard of care in multiple myeloma therapy. *Drugs*. 2022;82:613-631.
45. Bruno AS, Willson JL, Opalinska JM, et al. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma. *Expert Rev Hematol*. 2020;13(9):1017-1025.
46. Rasche L, Schinke C, Touzeau C, et al. Long-term efficacy and safety results from the phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. Presented at: The 2024 European Hematology Association (EHA) Annual Meeting; Abstract, 2024; Madrid, Spain and Virtual.
47. Ravi G, Bal S, Joiner L, et al. Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations. *Br J Haematol*. 2024;204(4):1300-1306.
48. Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. *Br J Haematol*. 2016;175(2):252-264.
49. Uckun FM. Cancer drug resistance in multiple myeloma. *Cancer Drug Resist*. 2022;5(2):271-276.
50. Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P. Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options. *Blood Rev*. 2021;49:100808.
51. Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. *Leukemia*. 2022;36:1371-1376.
52. Madduri D, Hagiwara M, Parikh K, et al. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. *Future Oncol*. 2021;17(5):503-515.
53. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia*. 2019;33(9):2266–2275.
54. Jagannath S, Lin Y, Goldschmidt H, et al. KarMMa-RW: a study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma

TALVEY™ (talquetamab-tgvs) US Prix Galien submission. [June 30th, 2025]

- (RRMM) and comparison of outcomes to KarMMa. *J Clin Oncol*. 2020;38(15 Suppl):8525 [abstract].
55. Kumar V, Ailawadhi M, Dutta N, et al. Trends in early mortality from multiple myeloma: a population-based analysis. *Clin Lymphoma Myeloma Leuk*. 2021;21(5):e449–e455.
 56. Robak P, Drozd I, Szemraj J, Robak T. Drug resistance in multiple myeloma. *Cancer Treat Rev*. 2018;70:199–208.
 57. Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. *Front Immunol*. 2023;14:1101495.
 58. ELREXFIO (elranatamab-bcmm). Prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf. Pfizer Inc. Last update Aug 2023. Accessed January 3, 2023.
 59. Granger K, Gaffney KJ, Davis JA. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. *J Oncol Pharm Pract*. 2023;29(3):722-726.
 60. Garfall AL, Nooka A, van de Donk NWCJ, et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. Presented at: The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31-June 4, 2024; Chicago, IL and virtual.
 61. Tomasson MH, Iida S, Niesvizky R, et al. Long-term efficacy and safety of elranatamab monotherapy in the phase 2 MagnetisMM-3 trial in relapsed or refractory multiple myeloma. Presented at: The 65th American Society of Hematology (ASH) Annual Meeting; December 9-12, 2023; San Diego, CA.
 62. Lin Y, Martin T, Usmani SZ, et al. MM-309 CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. Presented at: The 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2-6, 2023; Chicago, IL and virtual.
 63. van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. *Hematology Am Soc Hematol Educ Program*. 2020;2020(1):248-258.
 64. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. *Leukemia*. 2020;34(4):985-1005.
 65. Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. *Front Immunol*. 2018;9:1821.
 66. Cliff ERS, Reynolds G, Popat R, Teh BW, Kesselheim AS, Mohyuddin GR. Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma. *J Clin Oncol*. 2023;41(10):1949-1951.

67. Hammons LR, Szabo A, Janardan A, et al. Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma. *JAMA Netw Open*. 2022;5(10):e2238961.
68. Lancman G, Sastow DL, Cho HJ, et al. Bispecific antibodies in multiple myeloma: present and future. *Blood Cancer Discov*. 2021;2(5):423-433.
69. Gagelmann N, Ayuk FA, Klyuchnikov E, Wolschke C, Berger SC, Kroger N. Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients. *Haematologica*. 2023;108(10):2799-2802.
70. Rosinol L, Beksac M, Zamagni E, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. *Br J Haematol*. 2021;194(3):496-507.
71. Swan D, Murphy P, Glavey S, Quinn J. Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety. *Cancers (Basel)*. 2023;15(6).
72. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. *N Engl J Med*. 2023;388(11):1002-1014.
73. Beksac M, Seval GC, Kanellias N, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. *Haematologica*. 2020;105(1):201-208.
74. Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. *Haematologica*. 2014;99(2):360-364.
75. Pillarisetti K, Edavettal S, Mendonça M, et al. A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. *Blood*. 2020;135(15):1232-1243.
76. Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. *Blood Adv*. 2021;5(8):2196-2215.
77. Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. *Blood Cancer J*. 2024;14:24.
78. Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma. *N Engl J Med*. 2022;387(24):2232-2244.
79. Chari A, Touzeau C, Schinke C, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. *Lancet Haematol*. 2025;12(4):e269-e281.
80. Schinke CD, Touzeau C, Minnema MC, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab, a GPRC5D×CD3 bispecific antibody, for relapsed/refractory multiple

TALVEY™ (talquetamab-tgvs) US Prix Galien submission. [June 30th, 2025]

myeloma [poster 8036]. Presented at: The 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2–6, 2023; Chicago, IL, USA & Virtual.

81. TALVEY (talquetamab-tgvs). Prescribing information. 2023.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761342s000lbl.pdf. Janssen Biotech, Inc. Last update Aug 2023. Accessed January 3, 2023.
82. TALVEY. Summary of product characteristics. 2023.
https://www.ema.europa.eu/en/documents/product-information/talvey-epar-product-information_en.pdf. Janssen Biologics B.V. Accessed January 3, 2023.
83. Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. *Blood Cancer J.* 2024;14(1):158.
84. Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. *Immunol Cell Biol.* 2015;93(3):290-296.
85. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. *Blood Cancer J.* 2021;11(4):69.
86. Al Hadidi S, Heslop HE, Brenner MK, Suzuki M. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies. *Mol Ther.* 2024;32(8):2444-2460.
87. Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. *Sci Transl Med.* 2019;11(485):eaau7746.
88. Kodama T, Kochi Y, Nakai W, et al. Anti-GPRC5D/CD3 bispecific T-cell–redirecting antibody for the treatment of multiple myeloma. *Mol Cancer Ther.* 2019;18(9):1555-1564.
89. Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. *Eur J Clin Invest.* 2012;42(9):953-960.
90. van de Donk N, O'Neill C, de Ruijter MEM, Verkleij CPM, Zweegman S. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA. *Curr Opin Oncol.* 2023;35(6):601-611.
91. Goldsmith RB, Cornax I, Ma JY, Yao X, Peng P, Carreira V. Normal human tissue expression of G protein–coupled receptor class C group 5 member D (GPRC5D), a promising novel target for multiple myeloma, is restricted to plasma cells and hard keratinized tissues. Presented at: The International Myeloma Workshop; September 8-11, 2021; Vienna, Austria.
92. Hasselbalch Riley C, Hutchings M, Yoon S, et al. RG6234, a novel GPRC5D T-cell engaging bispecific antibody, induces rapid responses in patients with relapsed/refractory multiple myeloma: preliminary results from a first-in-human trial.

TALVEY™ (talquetamab-tgvs) US Prix Galien submission. [June 30th, 2025]

Presented at: The European Hematology Association Meeting; June 9-12, 2022; Vienna, Austria.

93. Burt R, Warcel D, Fielding AK. Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. *Hum Vaccin Immunother*. 2019;15(3):594-602.
94. Anonymous. FDA approves first bispecific. 2015. <https://www.nature.com/articles/nrd4531.pdf>. *Nat Rev Drug Discov*. Accessed April 21, 14.
95. Strohl WR, Naso M. Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells. *Antibodies (Basel)*. 2019;8(3):41.
96. Zhou X, Einsele H, Danhof S. Bispecific antibodies: a new era of treatment for multiple myeloma. *J Clin Med*. 2020;9(7):2166.
97. Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. *Acta Pharm Sin B*. 2018;8(4):539-551.
98. Hucks G, Rheingold SR. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL. *Blood Cancer J*. 2019;9:10.
99. Lejeune M, Köse MC, Duray E, Einsele H, Beguin Y, Caers J. Bispecific, T-cell-recruiting antibodies in B-cell malignancies. *Front Immunol*. 2020;11:762.
100. Touzeau C, Schinke C, Minnema MC, et al. Pivotal phase 2 MonumentAL-1 results of talquetamab, a GPRC5DxCD3 bispecific antibody, for relapsed/refractory multiple myeloma. Presented at: The European Hematology Association Congress; June 8-11, 2023; Frankfurt, Germany.
101. Johnson & Johnson. U.S. FDA approves TALVEY™ (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma. 2023. <https://www.jnj.com/media-center/press-releases/u-s-fda-approves-talvey-talquetamab-tgvs-a-first-in-class-bispecific-therapy-for-the-treatment-of-patients-with-heavily-pretreated-multiple-myeloma>. Accessed April 21, 2024.
102. Rasche L, Schinke C, Touzeau C, et al. Efficacy and safety from the phase 1/2 MonumentAL-1 study of talquetamab, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: analyses at an extended median follow-up. Presented at: The American Society of Clinical Oncology (ASCO) Annual Meeting; May 30-June 3, 2025; Chicago, IL, USA & Virtual.
103. Krishnan A, Costa LJ, Schinke C, et al. Talquetamab, a GPRC5DxCD3 bispecific antibody, in relapsed/refractory multiple myeloma: efficacy and safety of patient subgroups from MonumentAL-1. Presented at: The International Myeloma Society Annual Meeting; September 27-30, 2023; Athens, Greece.

104. Nooka AK, Rodriguez C, Mateos MV, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. *Cancer*. 2024;130(6):886-900.
105. Popat R, Laheij A, van de Donk NWCJ, et al. Prophylactic interventions for oral toxicities with the GPRC5DxCD3 bispecific antibody talquetamab in relapsed/refractory multiple myeloma: an update on the open-label, phase 2, randomized TALISMAN study. Presented at: The American Society of Clinical Oncology (ASCO) Annual Meeting; May 30-June 3, 2025; Chicago, IL, USA & Virtual.
106. Touzeau C, Chari A, Schinke C, et al. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody: patient-reported outcomes from MonumenTAL-1 [poster 1937]. Presented at: The 64th American Society of Hematology (ASH) Annual Meeting; December 10–13, 2022; New Orleans, LA, USA.
107. Dholaria B, Weisel K, Mateos MV, et al. Talquetamab + daratumumab in patients with relapsed/refractory multiple myeloma: updated TRIMM-2 results Presented at: The 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2–6, 2023; Chicago, IL, USA & Virtual.
108. Kumar S, Mateos M-V, Ye JC, et al. Phase 2 study of talquetamab + teclistamab in patients with relapsed/refractory multiple myeloma and extramedullary disease: RedirecTT-1. Presented at: The European Hematology Association (EHA) 2025 Hybrid Congress; June 12-15, 2025; Milan, Italy.
109. Searle E, Quach H, Biran N, et al. Talquetamab, a GPRC5DxCD3 bispecific antibody, in combination with pomalidomide in patients with relapsed/refractory multiple myeloma: safety and efficacy results from the phase 1b MonumenTAL-2 study [abstract]. Presented at: The European Hematology Association Annual Meeting; June 13-16, 2024; Madrid, Spain.
110. European Medicines Agency. Recommendations on eligibility to PRIME scheme. February 4, 2021. https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-25-29-january-2021_en.pdf. Accessed April 21, 2024.
111. BioSpace. Janssen submits biologics license application to U.S. FDA for talquetamab for the treatment of patients with relapsed or refractory multiple myeloma. December 9, 2022. <https://www.biospace.com/article/releases/janssen-submits-biologics-license-application-to-u-s-fda-for-talquetamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/>. Accessed April 21, 2024.
112. U.S. Food and Drug Administration. Search orphan drug designations and approvals, talquetamab-tgvs. 2021. <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=814921>. Accessed April 21, 2024.
113. Johnson & Johnson. Janssen announces U.S. FDA breakthrough therapy designation granted for talquetamab for the treatment of relapsed or refractory multiple myeloma.

TALVEY™ (talquetamab-tgvs) US Prix Galien submission. [June 30th, 2025]

- June 29, 2022. [https://www.inj.com/media-center/press-releases/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-talquetamab-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma#:~:text=June%2029%2C%202022%20\(RARITAN%2C,refractory%20multiple%20myeloma%2C%20who%20have](https://www.inj.com/media-center/press-releases/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-talquetamab-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma#:~:text=June%2029%2C%202022%20(RARITAN%2C,refractory%20multiple%20myeloma%2C%20who%20have). Accessed April 21, 2024.
114. Pharma Japan. Japan awards orphan tag to Janssen's talquetamab, 2 more APIs. 2024. <https://pj.jiho.jp/article/250635>. Accessed June 27 2025.
 115. European Medicines Agency. PRIME: priority medicines. 2024. <https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines>. Accessed April 21, 2024.
 116. PR Newswire. Janssen announces U.S. FDA breakthrough therapy designation granted for talquetamab for the treatment of relapsed or refractory multiple myeloma. 2022. <https://www.prnewswire.com/news-releases/janssen-announces-us-fda-breakthrough-therapy-designation-granted-for-talquetamab-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma-301577835.html>. Accessed April 21, 2024.
 117. Luo X, Du X, Lv X, Yang Y, Zhang X, Huang L. Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, 2020-2024. JAMA Netw Open. 2024;7(10):e2439080.
 118. Sakushima K, Takeda H, Aoi Y. Orphan drug designation and development in Japan: 25 years of experience and assessment. Nat Rev Drug Discov. 2021;20(12):893-894.
 119. Shin EY, Hong YJ, Lim KM, Kim TH, Lee JH. International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea. J Pharm Policy Pract. 2024;17(1):2354299.
 120. Goldsmith R, Cornax I, Ma JY, Yao X, Peng P, Carreira V. P-095: Normal human tissue expression of G-protein coupled receptor 5D (GPC5D), a promising novel target for Multiple Myeloma, is restricted to plasma cells and hard keratinized tissues. Clinical Lymphoma Myeloma and Leukemia. 2021;21:S91.
 121. Zhou D, Wang Y, Chen C, Li Z, Xu K, Zhao K. Targeting GPRC5D for multiple myeloma therapy. Journal of Hematology & Oncology. 2024;17(1):88.
 122. Salem DA, Maric I, Yuan CM, et al. Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma. Leuk Res. 2018;71:106-111.
 123. Dogan A, Siegel D, Tran N, et al. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer Journal. 2020;10(6):73.
 124. Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13(1):125.

TALVEY™ (talquetamab-tgvs) US Prix Galien submission. [June 30th, 2025]

125. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048-2060.
126. Cho SF, Lin L, Xing L, et al. BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma. Cancers (Basel). 2020;12(6):1473.
127. Maus MV, June CH. Zoom zoom: racing CARs for multiple myeloma. Clin Cancer Res. 2013;19(8):1917-1919.
128. Wudhikarn K, Perales MA. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2022;57(10):1477-1488.
129. Frerichs KA, Verkleij CPM, Mateos MV, et al. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Adv. 2024;8(1):194-206.
130. Rodriguez-Otero P, Schinke C, Chari A, et al. Analysis of infections and parameters of humoral immunity in patients with relapsed/refractory multiple myeloma treated with talquetamab monotherapy in MonumenTAL-1. Presented at: The 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2–6,, 2023; Chicago, IL, USA & Virtual.
131. Hipp S, Tai YT, Blanset D, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis *in vitro* and *in vivo*. Leukemia. 2017;31(10):2278.
132. Reynolds G, Cliff ERS, Mohyuddin GR, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7(19):5898-5903.
133. Jourdes A, Cellierin E, Touzeau C, et al. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study on the behalf of G2I and Intergroupe Francophone du Myelome. Clin Microbiol Infect. 2024;10.1016/j.cmi.2024.02.023.
134. Mazahreh F, Mazahreh L, Schinke C, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023;7(13):3069-3074.
135. TECVAYLI (teclistamab-cqyv). Prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761291s000lbl.pdf. Janssen Biotech, Inc. Last update Oct 2022. Accessed January 3, 2023.
136. Ma X, Gong J, Zhou J, et al. Efficacy, safety, pharmacokinetic, and pharmacodynamic support for talquetamab QW and Q2W dosing in patients with relapsed/refractory multiple myeloma: analyses from MonumenTAL-1. Presented at: The American Society of Clinical Oncology Annual Meeting; June 2-6, 2023; Chicago, IL.

137. Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. *Haematologica*. 2017;102(11):1913-1922.
138. Slavcev M, Spinelli A, Absalon E, et al. Results of a time and motion survey regarding subcutaneous versus intravenous administration of daratumumab in patients with relapsed or refractory multiple myeloma. *Clinicoecon Outcomes Res*. 2021;13:465-473.
139. Chari A, Oriol A, Krishnan A, et al. Efficacy and safety of less frequent/lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma: results from the phase 1/2 MonumenTAL-1 study. Presented at: The 65th American Society of Hematology Annual Meeting; December 9-12, 2023; San Diego, CA.
140. Einsele H, Moreau P, Bahlis N, et al. Comparative efficacy of talquetamab vs. current treatments in the LocoMMotion and MoMMent studies in patients with triple-class-exposed relapsed/refractory multiple myeloma. *Adv Ther*. 2024;41(4):1576-1593.
141. Ye JC, Biran N, Nair S, et al. Talquetamab vs real-world physician's choice of therapy: comparative efficacy in patients with triple-class exposed relapsed/refractory multiple myeloma. Presented at: The International Myeloma Society (IMS) 2023 Congress; September 27-30, 2023; Athens, Greece.
142. Chari A, Sanden SV, Pei L, et al. Matched-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma [poster P888]. Presented at: The European Hematology Association (EHA) 2023 Conference; June 8–11, 2023; Frankfurt, Germany.
143. Oriol A, Qi K, Londhe A, et al. Comparative effectiveness of talquetamab vs physician's choice therapy in triple-class exposed patients with relapsed/refractory multiple myeloma: a matched cohort analysis [poster P893]. Presented at: The European Hematology Association (EHA) 2023 Hybrid Congress; June 8–11, 2023; Frankfurt, Germany.
144. Martin T, Krishnan A, Yong K, et al. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. *EJHaem*. 2022;3(1):97-108.
145. Costa LJ, Lin Y, Cornell RF, et al. Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed/refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2022;22(5):326-335.
146. Weisel K, Martin T, Krishnan A, et al. Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs physician's choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS clinical trials for the treatment of patients with relapsed or refractory multiple myeloma. *Clin Drug Investig*. 2022;42(1):29-41.
147. Martin T, Usmani SZ, Schechter JM, et al. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene

- vicleucel in KarMMA for the treatment of patients with relapsed or refractory multiple myeloma. *Curr Med Res Opin.* 2021;37(10):1779-1788.
148. Einsele H, Moreau P, Bahlis N, et al. Updated comparative effectiveness of talquetamab vs real-world physician's choice of treatment in LocoMMotion and MoMMent for patients with triple-class exposed relapsed/refractory multiple myeloma. Presented at: The European Hematology Association (EHA) 2025 Hybrid Congress; June 12-15,, 2025; Milan, Italy.
 149. Reece D, Diels J, Van Sanden S, et al. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma. *Current Medical Research and Opinion.* 2024;40(10):1769-1783.
 150. Goldschmidt H, Ashcroft J, Szabo Z, Garderet L. Navigating the treatment landscape in multiple myeloma: which combinations to use and when? *Ann Hematol.* 2019;98:1-18.
 151. Dima D, Abdallah AO, Davis JA, et al. Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy. *Blood Cancer J.* 2024;14(1):90.
 152. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. *J Clin Oncol.* 2023;41(6):1265-1274.
 153. Costa LJ, Banerjee R, Mian H, et al. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. *Leukemia.* 2025;39(3):543-554.
 154. Letouze E, Moreau P, Munshi N, Samur M, Minvielle S, Touzeau C. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. *Blood Adv.* 2024;8(11):2952-2959.
 155. Biltibo EMD, Surapaneni M, Al Hadidi S, Suvannasankha A, Jayani-Kosarzycki RV. Current and Future Directions of Immunotherapies in Multiple Myeloma. *Am Soc Clin Oncol Educ Book.* 2025;45(3):e473316.
 156. Van Oekelen O, Nath K, Mouhieddine TH, et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. *Blood.* 2023;141(7):756-765.
 157. Liu R, Yang R, Xu X, et al. Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: a retrospective analysis of LEGEND-2. *Br J Haematol.* 2024;10.1111/bjh.19340.
 158. Del Giudice ML, Galimberti S, Buda G. Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents. *Cancer Immunol Immunother.* 2023;72(12):3931-3937.

TALVEY™ (talquetamab-tgvs) US Prix Galien submission. [June 30th, 2025]

159. Jakubowiak AJ, Anguille S, Karlin L, et al. Updated results of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1/2 MonumenTAL-1 study [poster 3377]. Presented at: The 65th American Society of Hematology (ASH) Annual Meeting; December 9–12, 2023; San Diego, CA, USA.
160. Mateos M-V, Jakubowiak A, Einsele H, et al. Talquetamab vs real-world physician's choice in patients with relapsed/refractory multiple myeloma and prior B-cell maturation antigen therapy: updated analysis of MonumenTAL-1 vs LocoMMotion/MoMMent. Presented at: The European Hematology Association (EHA) 2025 Hybrid Congress; June 12-15,, 2025; Milan, Italy.
161. Raje NS, Cohen AD, Patel KK, van de Donk NWCJ, Richter J, San-Miguel J. Practical aspects of immunotherapy: a report from the 20th International Myeloma Society (IMS) Annual Meeting. Clin Lymphoma Myeloma Leuk. 2024;10.1016/j.clml.2024.03.005.
162. Sanchez L, Schinke C, Krishnan A, et al. Clinical outcomes of subsequent therapies in patients with relapsed/refractory multiple myeloma following talquetamab treatment: analyses from the phase 1/2 MonumenTAL-1 study [poster 2007]. Presented at: The 65th American Society of Hematology (ASH) Annual Meeting; December 9–12, 2023; San Diego, CA, USA.
163. Tan MSY, Chen Y, Smith EL. Beyond BCMA: newer immune targets in myeloma. Blood Adv. 2024;8(16):4433-4446.
164. Kannan A, Jeffrey K, Misbah S, Ramasamy K. Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach. Blood Rev. 2025;72:101287.
165. Atrash S, Thompson-Leduc P, Tai M-H, et al. Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study. BMC Cancer. 2021;21(1):1207.
166. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018;378(6):518-528.
167. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384-394.
168. POMALYST® (pomalidomide) prescribing information. 2023. https://packageinserts.bms.com/pi/pi_pomalyst.pdf. Bristol-Myers Squibb Company. Last update Mar 2023. Accessed April 21, 2024.
169. Matous J, Biran N, Perrot A, et al. Talquetamab + Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results From the Phase 1b MonumenTAL-2 Study. Presented at: The 65th American Society of Hematology (ASH) Annual Meeting; December 9–12,, 2023; San Diego, CA, USA.

170. Nizar Bahlis NWvdD, Donna Reece, Manisha Bhutani, Bhagirathbhai Dholaria, Anita D'Souza, Thomas G Martin, John McKay, Alfred Garfall, Amrita Krishnan, Kalpana Bakshi, Lijuan Kang, Lien Vandenberg, Thomas Prior, Jaszianne Tolbert, Ajai Chari. Talquetamab + Daratumumab + Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma: Results From the Phase 1b TRIMM-2 Study. Presented at: International Myeloma Society (IMS) Annual Meeting; September 25-28, 2024; Rio de Janeiro, Brazil.
171. Holstein SA, Suman VJ, McCarthy PL. Update on the role of lenalidomide in patients with multiple myeloma. *Ther Adv Hematol*. 2018;9(7):175-190.
172. Ajay K Nooka TC, Anita D'Souza, Jeffrey V Matous, Peter M Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Cyrille Hulin, Hang Quach, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Gary E Mason, Thomas Renaud, Gurdeep Parmar. Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination With Daratumumab and Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results From the Phase 1b MonumenTAL-2 Study. Presented at: American Society of Hematology (ASH) Annual Meeting 2024.; December 7–10, 2024.; San Diego, CA, USA.
173. Ho M, Paruzzo L, Minehart J, et al. Extramedullary Multiple Myeloma: Challenges and Opportunities. *Curr Oncol*. 2025;32(3).
174. Zanwar S, Novak J, Howe MD, et al. The mutational landscape of extramedullary multiple myeloma reveals novel biological insights and a potential therapeutic targets for exploration. *Blood*. 2024;144:2744.
175. Touzeau C, Moreau P. How I treat extramedullary myeloma. *Blood*. 2016;127(8):971-976.
176. Cohen YC, Magen H, Gatt M, et al. Talquetamab + teclistamab in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated phase 1b results from RedirecTT-1 with <1 year of follow-up [abstract]. Presented at: The European Hematology Association; June 13-16, 2024; Madrid, Spain.
177. Cohen YC, Magen H, Gatt M, et al. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. *N Engl J Med*. 2025;392(2):138-149.
178. Janssen Research & Development, LLC. A study comparing talquetamab in combination with daratumumab or in combination with daratumumab and pomalidomide versus daratumumab in combination with pomalidomide and dexamethasone in participants with multiple myeloma that returns after treatment or is resistant to treatment (MonumenTAL-3). 2022. <https://classic.clinicaltrials.gov/ct2/show/NCT05455320>. Accessed April 21, 2024.
179. Janssen Research & Development, LLC. A study comparing talquetamab plus pomalidomide, talquetamab plus teclistamab, and elotuzumab, pomalidomide, and dexamethasone or pomalidomide, bortezomib, and dexamethasone in participants with relapsed or refractory myeloma who have received an anti-CD38 antibody and

TALVEY™ (talquetamab-tgvs) US Prix Galien submission. [June 30th, 2025]

lenalidomide (MonumenTAL-6). 2024.

<https://classic.clinicaltrials.gov/ct2/show/NCT06208150>. Accessed April 21 2024.

180. Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228-1263.
181. Dimopoulos MA, Richardson P, Lonial S. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22(7):460-473.